Results 31 to 40 of about 31,650 (136)

Myeloid/lymphoid neoplasm with eosinophilia and BCR/FGFR1 rearrangement with transformation to cortical T-lymphoblastic lymphoma and erythroid precursors: a case report

Journal of Medical Case Reports, 2023
Background Myeloproliferative neoplasms are a group of diseases with diverse biological and clinical characteristics. As a provisional separate entity, myeloid/lymphoid neoplasms with eosinophilia and genetic rearrangement have been described, which may ...
Alejandro Pineda Isaza, Santiago Castaño Quintero, Lisceth Paola Quintero González, Fabián Emiliano Ahumada Córdoba, Andrés Felipe Arbeláez Olivar, Juan Carlos Bravo Ocaña   +5 more
doaj   +1 more source

CAR T-cell therapy-transforming treatment of hematological malignancies

Asian Journal of Medical Sciences, 2023
Hematological malignancies are a significant cause of mortality and morbidity in all age groups. According to the Global Burden of Disease Cancer Collaboration, there were about one million incident cases of hematological malignancies worldwide in 2016 ...
Shah Newaz Ahmed , Arun Kumar
doaj   +1 more source

γδ T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases and Its Distinction from Other Mature γδ T-Cell Malignancies

Case Reports in Hematology, 2017
Gamma delta (γδ) T-cell antigen receptor (TCR) expression and its related T-cell differentiation are not commonly reported in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
Eric X. Wei, Vasiliki Leventaki, John K. Choi, Susana C. Raimondi, Elizabeth M. Azzato, Sheila A. Shurtleff, Menchu G. Ong, Diana M. Veillon, James D. Cotelingam, Rodney E. Shackelford   +9 more
doaj   +1 more source

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies

Frontiers in Oncology, 2022
T-cell malignancies can be divided into precursor (T-acute lymphoblastic leukemia/lymphoblastic lymphoma, T-ALL/LBL) and mature T-cell neoplasms, which are comprised of 28 different entities.
Kamila Polgárová, Kamila Polgárová, Pavel Otáhal, Cyril Šálek, Cyril Šálek, Robert Pytlík, Robert Pytlík   +6 more
doaj   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, EarlyView.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Synchronous childhood T-lymphoblastic lymphoma and B-cell precursor acute lymphoblastic leukemia associated with constitutional MMR deficiency syndrome –a case report

Frontiers in Oncology
We present a four-year-old girl with synchronous T-cell lymphoblastic lymphoma (T-LBL) and B-cell precursor acute lymphoblastic leukemia (BCP-ALL).Development of two lymphoid malignancies arising from completely different cell lineages was confirmed by ...
Joanna Bulsa, Agata Karolina Pastorczak, Joanna Taha, Wojciech Mlynarski, Łukasz Sędek, Tomasz Szczepanski   +5 more
doaj   +1 more source

Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma

Biomarker Research, 2022
Patients with relapsed/refractory early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) respond poorly to traditional therapy and have dismal prognosis.
Hai-ping Dai, Wei Cui, Qing-ya Cui, Wen-juan Zhu, Hui-min Meng, Min-qing Zhu, Xia-ming Zhu, Lin Yang, De-pei Wu, Xiao-wen Tang   +9 more
doaj   +1 more source

Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Measurable residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) is well established in bone marrow (BM) samples for acute myeloid leukemia (AML), but its use in peripheral blood (PB) remains less developed. We adapted a semi‐automated and well validated MFC‐MRD assay, originally developed for BM, to PB aiming to evaluate ...
Jonas Schadt, Malte von Bonin, Uta Oelschlägel, Christoph Röllig, Christian Thiede, Leo Ruhnke, Martin Bornhäuser, Sebastian Brenner, Maximilian Alexander Röhnert   +8 more
wiley   +1 more source

Rapid Progression of Mediastinal Tumor within a Few Days: A Case Report of T Cell Lymphoblastic Lymphoma

대한영상의학회지, 2016
T-cell lymphoblastic lymphoma is a highly aggressive tumor derived from lymphocyte of the thymus, which accounts for 2% of non-Hodgkin's lymphoma. The disease occurs most commonly in adolescent and young adult males.
Tae Ran Ahn, Young Kyung Lee, Hyun Jung Jun, Eun Ah Jung, Jin Sung Son   +4 more
doaj   +1 more source

Post‐Translational Modifications of Key Proteins in Hematologic Malignancies: Carcinogenic Mechanisms, Biomarker Potential, and New Therapeutic Strategies

iLABMED, EarlyView.
This article reviews the pivotal role of post‐translational modifications of proteins in the development and progression of hematologic malignancies, and explores their clinical translation potential as novel biomarkers and therapeutic targets. ABSTRACT Post‐translational modifications (PTMs) of proteins have emerged as critical regulators in the ...
Yuxuan Han, Chaowei Zhang, Weiyi Yao, Qing Hong, Xinyu Tang, Yanan Zhu, Na Chen   +6 more
wiley   +1 more source